Research programme: antibody therapeutics - Alder Biopharmaceuticals/Merck & Co
Latest Information Update: 13 Dec 2010
At a glance
- Originator Alder Biopharmaceuticals; Schering-Plough
- Developer Alder Biopharmaceuticals; Merck & Co
- Class Antibodies
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Unspecified